A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance
Journal of the Advanced Practitioner in Oncology · 04.03.2026 · 17 (7)
DOI: 10.6004/jadpro.2026.17.7.11 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Advanced Practitioner in Oncology, online erschienen am 04.03.2026. Verfasst von Kimberly Noonan und 5 weiteren Autor:innen. Beteiligte Einrichtung: From Simmons University, Boston, Massachusetts. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Monoclonal gammopathy of undetermined significance (MGUS) is characterized as a nonmalignant or premalignant state whereby monoclonal immunoglobulins are detected in plasma, urine, or both. Approximately 3% to 4% of the population over the age of 50 is diagnosed with MGUS. It is estimated that 1% will progress to multiple myeloma or lymphoma over 20 years and therefore require ongoing clinical monitoring. Monoclonal gammopathy of undetermined significance is categorized into three types that are determined by the paraprotein clone: immunoglobulin M (IgM) MGUS, non-IgM MGUS, and light chain MGUS. There are high-risk genetic, biochemical, and clinical factors that increase the risk of transformation to multiple myeloma or lymphoma. The incidence of MGUS is two- to threefold higher in the Black population compared with the White population, along with an earlier age of onset. Familial risk and modifiable lifestyle factors are also associated with the development of MGUS and multiple myeloma. Certain monoclonal gammopathies, known as monoclonal gammopathy of clinical significance (MGCS), are associated with various organs that are involved (kidney, brain, skin, lungs, liver, eyes, and heart). The most common MGCS are associated with renal and neurological abnormalities, and treatment may be considered. Early diagnosis and multidisciplinary approaches to mitigate organ damage and other complications are important for the recognition and management of MGCS. Monoclonal gammopathy of undetermined significance is monitored rather than treated unless there are clinical findings of progression or organ dysfunction. Ongoing research and clinical trials are essential to refine monitoring guidelines, develop targeted therapies, and explore preventive measures aimed at reducing progression to multiple myeloma and other malignancies.
Autor:innen und Institutionen
- From Simmons University, Boston, Massachusetts.
- VCU Massey Cancer Center, Richmond, Virginia.
- Winship Cancer Institute of Emory University, Atlanta, Georgia.
- Huntsman Cancer Institute, Salt Lake City, Utah.
- Dana-Farber Cancer Institute, Boston, Massachusetts.
Zitieren
APA
Noonan, K., Brigle, K., Gleason, C., Bellerive, C., Steinbach, M., & Doss, D. (2026). A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance. Journal of the Advanced Practitioner in Oncology, 17(7). https://doi.org/10.6004/jadpro.2026.17.7.11
Vancouver
Noonan K, Brigle K, Gleason C, Bellerive C, Steinbach M, Doss D. A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance. Journal of the Advanced Practitioner in Oncology. 2026;17(7). doi:10.6004/jadpro.2026.17.7.11
BibTeX
@article{Noonan2026,
author = {Noonan, Kimberly and Brigle, Kevin and Gleason, Charise and Bellerive, Carrie and Steinbach, Mary and Doss, Deborah},
title = {A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance},
journal = {Journal of the Advanced Practitioner in Oncology},
year = {2026},
volume = {17},
number = {7},
doi = {10.6004/jadpro.2026.17.7.11}
}
EUVIMED